N-Desethylprotonitazene
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral, intransal, vaporized |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C21H26N4O3 |
Molar mass | 382.464 g·mol−1 |
3D model (JSmol) | |
| |
|
N-Desethylprotonitazene is a benzimidazole opioid with potent analgesic effects which has been sold as a designer drug. It was first identified in 2024 as an active metabolite of the closely related compound protonitazene,[1][2] and was found to have less potency than it while still being more potent than fentanyl.[3][4]
It was discovered in a drug sample from Chicago in June 2025.[3]
See also
References
- ^ Ameline A, Gheddar L, Pichini S, Stove C, Aknouche F, Maruejouls C, et al. (Jul 2024). "In vitro characterization of protonitazene metabolites, using human liver microsomes, and first application to two urines collected from death cases". Clinica Chimica Acta; International Journal of Clinical Chemistry. 561 119764. Elsevier BV: 119764. doi:10.1016/j.cca.2024.119764. ISSN 0009-8981. PMID 38844019.
- ^ De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ, et al. (June 14, 2024). "In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids" (PDF). Archives of Toxicology. 98 (9). Springer Science and Business Media LLC: 2999–3018. Bibcode:2024ArTox..98.2999D. doi:10.1007/s00204-024-03774-7. ISSN 0340-5761. PMC 11324687. PMID 38877156. Retrieved July 19, 2025.
- ^ a b "Monographs". The Center for Forensic Science Research & Education. June 16, 2025. Retrieved July 19, 2025.
- ^ "Substance Details N-desethyl protonitazene". United Nations : Office on Drugs and Crime. Retrieved July 19, 2025.